Xencor Inc., of Monrovia, Calif., said it completed an underwritten public offering of 5.27 million shares of its common stock at $24 each, including 687,750 shares sold following the full exercise of an option previously granted to the underwriters to purchase additional shares of common stock. The gross proceeds were approximately $126.5 million with the net proceeds to be used for working capital and general corporate purposes, including additional investments in advancing its lead compound XmAb 5871 through later stages of clinical development and additional investment in its immune-oncology pipeline and technology.